

# GARDP's pipeline (March 2021)

DISCOVERY	DISEASE AREA		TRANSLATIONAL	DEVELOPMENT		REGULATORY	IMPLEMENTATION
			Pre-clinical / Early Clinical	Pediatric trials	Phase 3	Registration Status	Access Development
<b>AMR Screening Consortium</b> Eisai, Takeda & Daiichi S. <b>Antibiotic potentiators</b> Calibr / Scripps <b>Natural Products</b> HIPS	SERIOUS BACTERIAL INFECTIONS		Potential candidate A (NCE or repurposed)		Cefepime-taniborbactam (NCE) Venatorx Pharmaceuticals*		Access strategy
CHILDREN'S ANTIBIOTICS	NEONATAL SEPSIS	IV Fosfomycin	Treatment regimens Public health strategic efficacy and safety trials	Regulatory paediatric plans (serious bacterial infections paediatric and neonates)	Zoliflodacin (NCE) Entasis Therapeutics Inc.	Approved in EU, with Neo & Paeds label	Access strategy Including manufacturing development Surveillance / Prevalence studies
		Flomoxef				Approved in Asia: Neo & Paeds data	
		Amikacin				Approved globally: Neo & Paeds data	
	PAEDIATRIC DEVELOPMENT	Polymyxin B	Approved in USA, with limited Neo & Paeds label				
	Paediatric cefepime-taniborbactam (NCE) Venatorx Pharmaceuticals						
	Potential candidate A (NCE or repurposed)						
SEXUALLY TRANSMITTED INFECTIONS		Potential candidate B (NCE)			Approved in USA / EU for CABP		

\* Development of cefepime-taniborbactam is sponsored by Venatorx Pharmaceuticals and has been funded in whole or in part with federal funds from NIAID/NIH/HHS and BARDA/ASPR/HHS in the United States and The Wellcome Trust in the United Kingdom

